Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT04356755

Subcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma.

Led by University Hospital, Toulouse · Updated on 2025-12-31

32

Participants Needed

7

Research Sites

335 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Ischemic digital ulcers (DUs) are a frequent complication in systemic sclerosis with a major impact on hand function and quality of life. Digital injection of cultured adipose-derived stromal cell (AdMSC) constitutes a promising approach to treat scleroderma-induced refractory ischemic DUs where no alternative therapy is validated. The aim of this phase 2 study is to compare efficacy and safety of digital injection of AdMSC versus placebo for healing refractory active ischemic digital ulcers in patients with systemic sclerosis.

CONDITIONS

Official Title

Subcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma.

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female patient 18 years of age or older
  • Diagnosis of systemic sclerosis according to the 2013 ACR/EULAR classification criteria
  • Presence of at least one refractory active ischemic digital ulcer at the time of inclusion
  • For patients over 50 years, no hormone replacement therapy for at least 2 years and amenorrhea for at least 24 months prior to screening; serum follicle stimulating hormone > 40 TU/L may be used to confirm exclusion of childbearing potential
  • Ability to provide written informed consent
  • Ability to understand study requirements
  • Affiliated with a social security system
  • Each digital ulcer must be located beyond the proximal interphalangeal joint on the finger surface, be of ischemic origin, not over subcutaneous calcifications or bone, active, and refractory after 10±2 weeks of standard care
Not Eligible

You will not qualify if you...

  • Current smoker or tobacco use stopped less than 3 months before inclusion
  • Participation in a clinical trial within the previous 3 months
  • Use of statins for less than 3 months or unstable treatment
  • Use of vasodilators or related medications for less than 3 months or unstable treatment
  • Treatment with disease modifying agents within 1 month prior to study
  • Oral corticosteroids over 10 mg/day prednisone or equivalent
  • Systemic antibiotics for infected digital ulcers within 4 weeks prior to inclusion
  • Use of topical growth factors or hyperbaric oxygen
  • Local botulinum toxin injection in affected finger within 4 weeks prior to inclusion
  • Surgical sympathectomy or wound debridement in upper limbs within 1 month prior to inclusion
  • Liposuction technically impossible
  • Autologous hematopoietic stem cell transplant within 1 year
  • Indication for intensification by autologous HSCT
  • History of cancer in last 5 years except certain successfully treated skin cancers
  • Active proliferative retinopathy
  • Positive for HIV-1/2, HTLV-1/2, HBV, or HCV
  • History of stroke, myocardial infarction, or severe arrhythmia in last 6 months
  • Severe cardiac failure in last 6 months
  • Pregnant or breastfeeding females or planning pregnancy during study
  • Under judicial protection or refusal to participate
  • Digital ulcers due to non-scleroderma causes, non-ischemic ulcers, ulcers with osteomyelitis or uncontrolled infection, infected ulcers requiring systemic antibiotics, or ulcers requiring urgent surgery

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

Grenoble Hospital

Grenoble, France

Not Yet Recruiting

2

Lille Hopsital

Lille, France

Not Yet Recruiting

3

Marseille Hospital

Marseille, France

Not Yet Recruiting

4

Montpellier Hospital

Montpellier, France

Not Yet Recruiting

5

Nantes Hospital

Nantes, France

Not Yet Recruiting

6

Poitiers Hospital

Poitiers, France

Not Yet Recruiting

7

CHU de Toulouse - Hôpital PURPAN-TSA

Toulouse, France, 31059

Actively Recruiting

Loading map...

Research Team

G

Grégory PUGNET, MD, PHD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here